Merck: upcoming dates

Recent

• Business10/04/2026@EconDesk

  Merck Q2 2026: US$16.6 Billion Sales, Hikes Revenue Outlook, Terns Charge Hits Profit

  126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.

  

  Starts 08/04/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better61 days agoMerck's^[1][3] release is dated August 4, 2026 (6:30 am EDT) and CNBC's^[2] coverage is 'Published Tue, Aug 4 2026'.

  On 4 August 2026 Merck reported second-quarter sales of US$16.6 billion, up 5 percent, with Keytruda at US$8.4 billion, and raised its 2026 sales outlook while a US$2.31 per share Terns charge caused a loss.

  00
• Health10/04/2026@HealthDesk

  FDA Approves Merck's Lipfendra, the First Oral PCSK9 Inhibitor

  126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.

  

  Starts 07/16/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better80 days agoMerck's^[1][2] news release is dated July 16, 2026 and says the FDA 'has approved LIPFENDRA (enlicitide) tablets 20 mg'; Practical Neurology^[4] and the Family Heart^[5] Foundation report the same.

  On 16 July 2026 the FDA approved Merck's Lipfendra (enlicitide), a once-daily 20 mg tablet and the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia.

  00
• Business10/04/2026@EconDesk

  Merck to Buy Terns for US$6.7 Billion for a Leukemia Drug

  126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.

  

  Starts 03/25/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better193 days agoThe Merck and Terns news release (SEC^[1] Exhibit 99.1) is datelined 'RAHWAY, N.J., and FOSTER CITY, Calif., March 25, 2026' and Pharmaceutical Technology reported it the same day.

  On 25 March 2026 Merck agreed to acquire Terns Pharmaceuticals for US$53.00 per share in cash, about US$6.7 billion, to get TERN-701, an oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia.

  $6.7B

  00
• Business10/04/2026@EconDesk

  Merck Completes Cidara Takeover to Add a Long-Acting Flu Antiviral

  126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.

  

  Starts 01/07/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better270 days agoMerck's^[1][3] release, dated January 7, 2026, says it 'today announced the successful completion of the cash tender offer' for Cidara, with the tender expiring 11:59 p.m. ET on January 6.

  On 7 January 2026 Merck announced the completion of its cash tender offer for Cidara Therapeutics at US$221.50 per share, gaining CD388, a long-acting antiviral for preventing influenza.

  00
• Health10/04/2026@HealthDesk

  FDA Approves Merck's Keytruda, the First Anti-PD-1 Cancer Drug in the US

  126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.

  

  Starts 09/04/2014CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better12.1 years agoMerck's^[1] release is dated September 4, 2014 and says the FDA 'has approved KEYTRUDA'; The Pharmaletter^[3] (5 September 2014) reports the agency announced it 'late yesterday'.

  On 4 September 2014 the FDA granted accelerated approval to Merck's Keytruda (pembrolizumab) for advanced melanoma, the first anti-PD-1 therapy approved in the United States.

  00